Structure Therapeutics (NASDAQ:GPCR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a strong sell rating to a sell rating in a research note issued to investors on Monday.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright lowered their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Citizens Jmp cut their price objective on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Finally, Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $54.13 on Monday. The company’s fifty day moving average price is $50.03 and its 200-day moving average price is $51.89. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of -54.13 and a beta of -1.43. Structure Therapeutics has a one year low of $18.26 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts expect that Structure Therapeutics will post -1.84 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP grew its stake in shares of Structure Therapeutics by 1.6% during the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after buying an additional 119,146 shares during the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $1,041,000. Seven Fleet Capital Management LP bought a new stake in shares of Structure Therapeutics in the 1st quarter valued at about $434,000. Avidity Partners Management LP purchased a new stake in Structure Therapeutics during the 1st quarter valued at about $1,446,000. Finally, Bank of America Corp DE boosted its holdings in Structure Therapeutics by 617.0% during the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock valued at $10,948,000 after acquiring an additional 195,454 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.